This printed article is located at http://cordlife.listedcompany.com/directors.html
Dr Goh Jin Hian was first appointed as a Director of the Company in July 2011 and was last re-elected on October 28, 2016. He was re-designated as Chairman of the Board in March 2018.
He is also currently an Executive Director and Chief Executive Officer of SGX-listed New Silkroutes Group. Prior to joining New Silkroutes Group, Dr Goh was a C-suite executive in Parkway Health from 1999-2011 and an Executive Director in a private oil and gas company from 2012 – 2014.
He had also served on the Council of Singapore Human Resource Institute from 2007 to 2017 and on the Council of the Singapore Medical Association from 1996 to 2000.
Dr Goh obtained his Bachelor of Medicine and Bachelor of Surgery from the National University of Singapore in 1992. He also holds a Master of Business Administration from the University of Hull. In addition, Dr Goh completed The Wharton Advanced Management Program in 2005.
Dr Ho Choon Hou was frst appointed as a Director of the Company in June 2011 and was last re-elected on October 28, 2016. He was re-designated as an Independent Director on May 22, 2018.
Dr Ho is a Principal at Southern Capital Group Limited, where he is responsible for the origination and execution of investments. He is also an Independent Director of Advanced Holdings Limited and Mclean Berhad.
Dr Ho holds a Bachelor of Medicine and Bachelor of Surgery (Honours) from the University of Sheffield, as well as a Master of Medicine (Surgery) from the National University of Singapore and a Master of Business Administration (Honours) from the University of Chicago (Graduate School of Business).
Mr Michael Steven Weiss serves as Group Chief Executive Officer (appointed on February 12, 2018) and Executive Director, Business Development and Mergers & Acquisitions (appointed on February 1, 2017) for the Group. Prior to his re-designation, he was appointed as a Non-Independent, Non-Executive Director of the Company on November 1, 2016.
Mr Weiss has over 20 years of experience in the finance and investment sectors in North America and Asia, and has served on several investment committees and corporate boards, including those of healthcare companies, where he advised CEOs and CFOs on strategic initiatives, human resource management, financial planning and public and private capital raising.
Prior to his current positions, Mr Weiss was a Partner and Managing Director at cross-border private equity firm, Sailing Capital, China’s largest RMB overseas investment fund. He also served as Managing Director of Morgan Stanley’s China mergers advisory unit and held investment banking positions at Credit Suisse Group and Citigroup, where he executed over $20 billion in M&A and capital markets transactions.
Mr Weiss obtained his Master of Arts in Regional Studies East Asia, focusing on Chinese business history, from Harvard University. He also holds a Bachelor degree in East Asian Studies from Northwestern University and is ﬂuent in Mandarin Chinese.
Mr Joseph Wong Wai Leung was appointed as an Independent Director of the Company on September 23, 2014 and was last re-elected on October 17, 2014.
Mr Wong has a wealth of experience in the financial services industry. He started his career at Big Four auditing firms PricewaterhouseCoopers and Deloitte Touche Tohmatsu, Hong Kong (“Deloitte”).
At Deloitte, he was engaged in a wide spectrum of business domains, including initial public offerings, taxation, and asset protection plans for high net worth individuals. Subsequently, he worked at Credit Agricole (Suisse), Hong Kong, where he advised clients on wealth management.
Mr Wong holds a Bachelor of Commerce from the University of Calgary in Alberta, Canada.
Mr Yeo Hwee Tiong was appointed as an Independent Director of the Company on May 22, 2018.
Mr Yeo is currently the Group Chief Executive Officer with the Singapore Women’s & Children’s Medical Group. He has more than 28 years in the healthcare and project management industry and has been involved in the pre-development and planning, construction, project management, hospital management and restructuring of hospitals in Singapore, Malaysia, Myanmar and Vietnam. Mr Yeo was instrumental in the restructuring and turning around of three hospitals in Singapore and Malaysia. Of these, he listed two in Singapore. Mr Yeo also has experience in Vietnam, taking a greenfield hospital project from inception to completion, and into hospital management. On project management sector, Mr Yeo has been involved at senior level in Singapore, India, Vietnam and New Zealand where he project managed large office complexes, air terminals, industrial park, microwave tower , medical centres and hospitals.
Prior to his current portfolio, Mr Yeo was the Principal at KPMG, Deal Advisory, Healthcare (Singapore and Asia Pacific). He was responsible in setting up the healthcare division for KPMG Singapore and was also appointed as the Healthcare Lead for Asia Pacific working alongside KPMG Global Healthcare based in UK. Mr Yeo led in many clients’ engagements on the healthcare landscape in Myanmar, Vietnam, India, Thailand, Indonesia, Philippines, China, Sri Lanka, Malaysia and presented many market entry opportunities and advisory services to KPMG’s clients. He was also involved in commercial due diligence , market research , M&A , restructuring , greenfield advisory, business improvements and clinical due diligence of medical practices and hospitals in Singapore and in the region.
Mr Yeo has managed public hospital in Singapore and private hospitals in Singapore, Malaysia and Vietnam and as its Group CEO, has clear oversight responsibility in ensuring the proper management of the hospitals under his charge.
Mr Yeo obtained his Bachelor of Science (Building) from Heriot-Watt University, Edinburgh, United Kingdom. He also holds a Master of Science (Project Management) from National University of Singapore.
Mr Albert Chen was appointed as a Non-Independent, Non-Executive Director of the Company on April 29, 2016 and was last re-elected on October 28, 2016.
Mr Chen is the Chief Financial Officer and Director of NYSE-listed China Cord Blood Corporation (“CCBC”), where he oversees finance-related matters including accounting and budget planning. He is also involved in CCBC’s corporate structuring and development, including mergers and acquisitions, and investment in foreign healthcare companies.
Mr Chen had previously served as the vice-president of corporate finance at Golden Meditech Holdings Limited since March 2005, prior to which he worked in financial institutions such as Salomon Smith Barney, DBS Vickers Securities and UOB Kay Hian in Hong Kong.
Mr Chen is a CFA charterholder. He holds a Bachelor in Commerce from Queen’s University in Canada, with a major in Finance and Accounting.
Ms Christine Wong was appointed as a Non-Independent, Non-Executive Director of the Company on November 1, 2016.
Ms Wong has been the Senior Investment Director of Kunlum Investment Holding Limited ("Kunlum") since November 2015. Prior to joining Kunlum, she was the Managing Director at CBW Consulting, Inc. (“CBW”) for 10 years. CBW is a consulting firm that focuses on United States-China relations and business projects.
Ms Wong holds a Bachelor in Business Administration from Hofstra University.
Mr Bu Jiang Yong was appointed as a Non-Independent, Non-Executive Director of the Company on May 22, 2018.
Mr Bu is currently the Senior Vice President of Sanpower Group and Chairman of its Healthcare Business Group. He is also serving as the Board Director of Nanjing Xinjiekou Department Store Co., Ltd (600682.SH). Mr Bu has managed numerous domestic and overseas companies in the area of genetic testing, cell immunotherapy, hospital management, senior care and health management within Sanpower, amongst which are Dendreon, Natali, An Kang Tong, Mecox Lane, More Health, Findgene as well as Xuzhou Third People's Hospital. He has also led successful mergers and acquisitions within China and cross-border. Furthermore, he spearheaded and completed numerous projects of material asset reorganisation of the listed company.
Prior to his current position, Mr Bu was the co-founder and CEO of Sunda Auto Service Co., Ltd, a leader in auto services and online auto insurance platform in China. He had also previously served as a General Manager at Shanghai Yongle Home Appliance Co., Ltd, where he grew the business by at least 10-fold.
Mr Bu obtained a Bachelor in Precision Instruments from Tianjin University. He also holds an Executive Master of Business Administration from CEIBS.
Ms Wang Tongyan was appointed as a Non-Independent, Non-Executive Director of the Company on May 4, 2017.
Ms Wang has more than 22 years of experience in the pharmaceutical industry, specialising in market management. She is currently the Vice President of Sanpower Group (“Sanpower”), where she oversees biomedical group strategies and medical industry management. Prior to joining Sanpower, she was the Vice President of Image Innovation at Nanchang China Sciences Group and Chief Operating Officer at CSG Jiufeng Mobile Health Care Co., Ltd.
Ms Wang previously also served as the Vice President of Janssen Pharmaceutical Co., Ltd of US Johnson & Johnson Group, where she was Chief Marketing Officer and sales director. She also holds various public posts, such as Vice President of the China Pharmaceutical Industry Association.
Ms Wang holds a PhD in theoretical research from the University of Lisbon, as well as a Master in Business Administration and a Bachelor of Clinical Medicine from Xi’an Jiaotong University.